Abstract
Background and aims: Every year hepatocellular carcinoma (HCC) develops in about 3–4% of cirrhotic patients. The squamous cell carcinoma antigen (SCCA) was found elevated in liver cancer specimens by immunohistochemistry and detected by ELISA complexed with IgM (SCCA-IgM) in serum of patients with HCC. This study aimed to evaluate the ability of SCCA-IgM serum levels to predict the efficacy of HCC therapy.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call